1. Redefining anthracycline‐related subclinical cardiotoxicity: ‘Absolute’ and ‘relative’ change in longitudinal strain
- Author
-
Andrew Terluk, Luke Stefani, Anita Boyd, Kim Vo, Karen Byth, Rina Hui, David Richards, and Liza Thomas
- Subjects
Anthtracycline chemotherapy ,Breast cancer ,Global longitudinal systolic strain ,Transthoracic echocardiography ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims Anthracycline chemotherapy (AC) for breast cancer can cause cancer therapy‐related cardiac dysfunction (CTRCD) with resultant heart failure, traditionally defined as a reduction in left ventricular (LV) ejection fraction on echocardiography. In recent years, global longitudinal systolic strain (GLS) has been used to identify subclinical cardiac dysfunction prior to development of overt CTRCD. Recent harmonized guidelines have incorporated GLS into definitions for CTRCD to identify cardiac dysfunction and inform decisions regarding cardioprotective strategies. Methods and results We evaluated subclinical dysfunction in breast cancer patients treated with AC and determined the echocardiographic and patient factors associated with significant GLS changes. One hundred fourteen HER2 negative patients treated with AC were prospectively recruited and underwent serial echocardiograms (LVEF and LVGLS) at three time points (prior to AC, 3 months, and 1 year). CTRCD was defined as an asymptomatic reduction in LVEF of 10% or symptomatic drop of 5% to LVEF
- Published
- 2024
- Full Text
- View/download PDF